Revvity Sites Globally

Select your location.

*e-commerce not available for this region.

Australia

Austria

Belgium

Brazil *

Canada

China *

Denmark

Finland

France

Germany

Hong Kong (China) *

India *

Ireland

Italy

Japan *

Luxembourg

Mexico *

Netherlands

Norway

Philippines *

Republic of Korea *

Singapore *

Spain

Sweden

Switzerland

Thailand *

United Kingdom

United States

Respiratory SARS-CoV-2 RT-PCR Panel 1, 96 rxns

EUA authorization for the simultaneous detection of SARS-CoV-2, influenza A, Influenza B, and RSV viruses.

The FDA EUA authorized Respiratory SARS-CoV-2 RT-PCR Panel 1 is a real-time RT-PCR multiplexed test intended for the simultaneous qualitative detection and differentiation of SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus (RSV) from nasopharyngeal swabs, anterior nasal swabs, and mid-turbinate swabs, collected from individuals suspected by a healthcare provider of having respiratory viral infection consistent with COVID-19. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high complexity tests, or by similarly qualified non-U.S. laboratories.

View product information

EUA authorization for the simultaneous detection of SARS-CoV-2, influenza A, Influenza B, and RSV viruses.

View product information

Product variant

For emergency use authorization only. Products may not be licensed in accordance with the laws in all countries. Please check with your local representative for availability.

Request more information

Product information

Overview

pkamp respiratory sars-cov-2 rt pcr panel 1

Conserve time and reagents while delivering relevant, accurate, and actionable results

As described in the kit insert, this RT-PCR assay targets two specific genomic regions of SARS-CoV-2: the nucleocapsid (N) gene and ORF1ab. Thus, mutations in spike protein, as seen in many Variants of Concern, do not significantly impact the safety or effectiveness of our assays.

Efficient Processing: Resource conservation by allowing simultaneous detection of SARS-CoV-2, influenza A, influenza B, and RSV
Scalable Workflows: Allow laboratories to scale their testing up or down

Respiratory SARS-CoV-2 RT-PCR panel 1 primers and controls

The oligonucleotide primers and probes for detection of SARS-CoV-2 were selected from the regions of the virus nucleocapsid (N) gene and ORF1ab gene. The primers and probes for detection of influenza A and RSV were selected from the regions of matrix protein. The primers and probes for detection of influenza B were selected from the regions of nuclear export protein (NEP) and nonstructural protein 1 (NS1) genes. An additional primer/probe set to detect the endogenous control gene RNase P is also included in the test. It is used for monitoring human biological material and extraction efficiency.

Probes for the amplicons of SARS-CoV-2, Influenza A, Influenza B, RSV and RNase P are labeled with FAM, ROX, Cy5, Cy5.5 and HEX/VIC fluorescent dyes respectively to generate target-specific signals.

The assay also uses a dUTP/UNG carryover prevention system to avoid contamination of PCR products and subsequent false positive results. Additionally, this kit includes positive, negative, and internal controls to prevent the reporting of incorrect results.

Rapid, high quality RNA extraction of viral RNA for respiratory RT-PCR testing

The chemagic™ Viral DNA/ RNA 300 kit H96 and chemagic 360 instrument deliver fast, high quality RNA extraction from nasopharyngeal, anterior nasal swabs, and mid-turbinate swabs. The samples can be used to prepare specimens for use with the Respiratory SARS-CoV-2 RT-PCR Panel 1.